False-positive screening results in the European randomized study of screening for prostate cancer

Tuomas P. Kilpeläinen; Teuvo L.J. Tammela; Monique Roobol; Jonas Hugosson; Stefano Ciatto; Vera Nelen; Sue Moss; Liisa Määttänen; Anssi Auvinen

doi:10.1016/j.ejca.2011.06.055

journal article Dec 01, 2011

False-positive screening results in the European randomized study of screening for prostate cancer

Tuomas P. Kilpeläinen

Teuvo L.J. Tammela Monique Roobol Jonas Hugosson Stefano Ciatto Vera Nelen Sue Moss Liisa Määttänen Anssi Auvinen

European Journal of Cancer Vol. 47 No. 18 pp. 2698-2705 · Elsevier BV

View at Publisher Save 10.1016/j.ejca.2011.06.055

Topics

No keywords indexed for this article. Browse by subject →

References

31

[1]

Screening and Prostate-Cancer Mortality in a Randomized European Study

Fritz H. Schröder, Jonas Hugosson, Monique J. Roobol et al.

New England Journal of Medicine 2009 10.1056/nejmoa0810084

[2]

Draisma "Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context" J Natl Cancer Inst (2009) 10.1093/jnci/djp001

[3]

Etzioni "Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends" J Natl Cancer Inst (2002) 10.1093/jnci/94.13.981

[4]

Määttänen "Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial" Br J Cancer (2007) 10.1038/sj.bjc.6603522

[5]

Kilpeläinen "False-positive screening results in the Finnish prostate cancer screening trial" Br J Cancer (2010) 10.1038/sj.bjc.6605512

[6]

Croswell "Cumulative incidence of false-positive results in repeated, multimodal cancer screening" Ann Fam Med (2009) 10.1370/afm.942

[7]

Nelen "ERSPC: features and preliminary results from the Antwerp study centre" BJU Int (2003) 10.1111/j.1464-410x.2003.04391.x

[8]

Mäkinen "Second round results of the Finnish population-based prostate cancer screening trial" Clin Cancer Res (2004) 10.1158/1078-0432.ccr-03-0338

[9]

Ciatto "Specific features of the Italian section of the ERSPC" BJU Int (2003) 10.1111/j.1465-5101.2003.04394.x

[10]

Roobol "Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam" J Natl Cancer Inst (2007) 10.1093/jnci/djm101

[11]

Roobol "Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)" Eur Urol (2009) 10.1016/j.eururo.2009.07.018

[12]

Mäkinen "Acceptability and complications of prostate biopsy in population-based PSA screening versus routine clinical practice: a prospective, controlled study" Urology (2002) 10.1016/s0090-4295(02)01864-2

[13]

Carlsson S, Holmberg E, Moss S, et al. No excess mortality after prostate biopsy – Results from the European Randomized Study of Screening for Prostate Cancer (ERSPC). BJU Int [Epub 2010, Oct 15].

[14]

Fowler "The impact of a suspicious prostate biopsy on patients’ psychological, socio-behavioral and medical care outcomes" J Gen Intern Med (2006) 10.1111/j.1525-1497.2006.00464.x

[15]

Lafata "The economic impact of false-positive cancer screens" Cancer Epidemiol Biomarkers Prev (2004) 10.1158/1055-9965.2126.13.12

[16]

Finne "Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0μg per liter" Eur Urol (2008) 10.1016/j.eururo.2007.10.056

[17]

Finne "Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening" Int J Cancer (2004) 10.1002/ijc.20250

[18]

Schröder "Does PSA velocity predict prostate cancer in pre-screened populations?" Eur Urol (2006) 10.1016/j.eururo.2005.12.026

[19]

Etzioni "Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence" J Natl Cancer Inst (2007) 10.1093/jnci/djm171

[20]

Bangma "On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer" Eur J Cancer (2010) 10.1016/j.ejca.2010.09.031

[21]

Gupta "A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands" Br J Cancer (2010) 10.1038/sj.bjc.6605815

[22]

Jansen "Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection" Eur Urol (2010) 10.1016/j.eururo.2010.02.003

[23]

Epidemiology of prostatitis in Finnish men: a population‐based cross‐sectional study

A. Mehik, P. Hellström, O. Lukkarinen et al.

BJU International 2000 10.1046/j.1464-410x.2000.00836.x

[24]

Rhodes "Longitudinal prostate growth rates during 5 years in randomly selected community men 40–79years old" J Urol (1999) 10.1016/s0022-5347(01)61621-5

[25]

Wright "Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging" J Urol (2002) 10.1016/s0022-5347(05)65010-0

[26]

Nelen "Interval cancers in the Antwerp European randomised study of screening for prostate cancer study, using a 6 year screening interval" Eur J Cancer (2010) 10.1016/j.ejca.2010.09.024

[27]

Auvinen "Test sensitivity in the European prostate cancer screening trial: results from Finland, Sweden, and the Netherlands" Cancer Epidemiol Biomarkers Prev (2009) 10.1158/1055-9965.epi-09-0146

[28]

Finne "Lead-time in the European randomised study of screening for prostate cancer" Eur J Cancer (2010) 10.1016/j.ejca.2010.09.034

[29]

Ford "Effects of false positive prostate cancer screening results on subsequent prostate cancer screening behavior" Cancer Epidemiol Biomarkers Prev (2005) 10.1158/1055-9965.190.14.1

[30]

Roobol "A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer" Eur Urol (2010) 10.1016/j.eururo.2009.08.025

[31]

Otto "PSA levels and cancer detection rate by centre in the European randomized study of screening for prostate cancer" Eur J Cancer (2010) 10.1016/j.ejca.2010.09.012

Metrics

57

Citations

31

References

Details

Published: Dec 01, 2011
Vol/Issue: 47(18)
Pages: 2698-2705
License: View

Authors

T

Tuomas P. Kilpeläinen

Department of Urology, Sahlgrenska Academy at Goteborg University, Gothenburg, Sweden

Provincial Institute for Hygiene, Antwerp, Belgium

Prostate Cancer Research Center, Faculty of Social Sciences, Tampere University, Tampere, Finland

Funding

Beckman-Coulter-Hybritech Inc

Cite This Article

Tuomas P. Kilpeläinen, Teuvo L.J. Tammela, Monique Roobol, et al. (2011). False-positive screening results in the European randomized study of screening for prostate cancer. European Journal of Cancer, 47(18), 2698-2705. https://doi.org/10.1016/j.ejca.2011.06.055

False-positive screening results in the European randomized study of screening for prostate cancer

You May Also Like